Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
J Infect
    August 2025
  1. VALENTINA M, Giulia M, Eleonora C, Alessandro C, et al
    Humoral and T-Cell Responses Following MVA-BN Booster Vaccination Against Mpox Virus Clades Ib and IIb.
    J Infect. 2025 Aug 25:106602. doi: 10.1016/j.jinf.2025.106602.
    >> Share

  2. LIU B, Song S, Liu W, Hu Y, et al
    Post-COVID-19 multimorbidity incidence by prior vaccination status in people with a pre-existing comorbidity: A population-based cohort study.
    J Infect. 2025;91:106597.
    >> Share

  3. AHIMBISIBWE G, Greenwood D, Wilkinson KA, Gahir J, et al
    Third exposure to COVID-19 infection or vaccination differentially impacts T Cell responses.
    J Infect. 2025 Aug 21:106598. doi: 10.1016/j.jinf.2025.106598.
    >> Share

  4. MCGEOCH LJ, Foulkes S, Whitaker H, Munro K, et al
    Effectiveness of influenza vaccination against infection in UK healthcare workers during winter 2023-24: The SIREN cohort study.
    J Infect. 2025;91:106585.
    >> Share

  5. LADHANI SN, Mandal S, Mohammed H, Saunders J, et al
    The United Kingdom meningococcal vaccine (4CMenB) programme against gonorrhoea: a review of the evidence and knowledge gaps.
    J Infect. 2025 Aug 7:106582. doi: 10.1016/j.jinf.2025.106582.
    >> Share

  6. JANANI L, Munro APS, Wright A, Aley PK, et al
    Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
    J Infect. 2025 Aug 7:106576. doi: 10.1016/j.jinf.2025.106576.
    >> Share

  7. JEGEDE B, Zhou Y, Hawksworth H, Hui DS, et al
    Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged >/=50 years with a history of herpes zoster: a phase 3, randomized controlled trial.
    J Infect. 2025 Aug 6:106573. doi: 10.1016/j.jinf.2025.106573.
    >> Share

  8. TILEY KS, Ten Hulscher-van Overbeek H, Basnet S, van Binnendijk R, et al
    The waning of maternal measles antibodies: A multi-country maternal-infant seroprevalence study.
    J Infect. 2025;91:106531.
    >> Share

    June 2025
  9. KALKERI R, Zhu M, Cloney-Clark S, Parekh A, et al
    Anti-Spike IgG4 and Fc Effector Responses: The Impact of SARS-CoV-2 Vaccine Platform-Specific Priming and Immune Imprinting.
    J Infect. 2025 Jun 26:106543. doi: 10.1016/j.jinf.2025.106543.
    >> Share

  10. RIVERA-IZQUIERDO M, Verdejo-Ianez A, Morales-Portillo A, Gonzalez-Alcaide M, et al
    High-dose versus standard-dose influenza vaccine for immunocompromised patients: A systematic review and meta-analysis of randomised clinical trials.
    J Infect. 2025;91:106538.
    >> Share

  11. BERTRAN M, Abdullahi F, D'Aeth JC, Amin-Chowdhury Z, et al
    Recurrent invasive pneumococcal disease in children: A retrospective cohort study, England, 2006/07-2017/18.
    J Infect. 2025;90:106490.
    >> Share

    May 2025
  12. OLIVEIRA LVN, Hargarten JC, Wang R, Carlson D, et al
    Peripheral blood CD4(+) and CD8(+) T cell responses to Cryptococcus candidate vaccine antigens in human subjects with and without cryptococcosis.
    J Infect. 2025;91:106521.
    >> Share

  13. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Corrigendum to "Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: A cohort study" [J Infect 90 (2025) 106497].
    J Infect. 2025;91:106522.
    >> Share

  14. CHACON GP, McAlister S, Totterdell J, Estcourt MJ, et al
    Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines.
    J Infect. 2025 May 23:106515. doi: 10.1016/j.jinf.2025.106515.
    >> Share

    April 2025
  15. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
    J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
    >> Share

  16. SEPPANEN EJ, Bayliss J, Clark SL, Gamez C, et al
    Haemophilus influenzae remains the predominant otitis media pathogen in Australian children undergoing ventilation tube insertion in the PCV13 era.
    J Infect. 2025;90:106478.
    >> Share

    March 2025
  17. PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al
    Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
    J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473.
    >> Share

  18. WARD T, Paton RS, Overton CE, Mellor J, et al
    Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey.
    J Infect. 2025 Mar 5:106461. doi: 10.1016/j.jinf.2025.106461.
    >> Share

    February 2025
  19. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
    The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose.
    J Infect. 2025 Feb 18:106447. doi: 10.1016/j.jinf.2025.106447.
    >> Share

  20. WILLIAMS KV, Krauland MG, Nowalk MP, Harrison LH, et al
    Increasing child vaccination coverage can reduce influenza cases across age groups: An agent-based modeling study.
    J Infect. 2025;90:106443.
    >> Share

  21. NOBLE C, McDonald E, Nicholson S, Biering-Sorensen S, et al
    Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.
    J Infect. 2025 Feb 6:106436. doi: 10.1016/j.jinf.2025.106436.
    >> Share

  22. ZIMAKOFF AC, Jensen A, Malon M, Sorensen JK, et al
    Measles-mumps-rubella vaccination at 6 months of age and the risk of atopic disease in the first year of life: Results from a Danish placebo-controlled randomised trial.
    J Infect. 2025 Feb 2:106433. doi: 10.1016/j.jinf.2025.106433.
    >> Share

    January 2025
  23. BENNETT C, Chau G, Clayton E, Chu L, et al
    Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial.
    J Infect. 2025 Jan 26:106428. doi: 10.1016/j.jinf.2025.106428.
    >> Share

  24. YANG Y, Knoll MD, Herbert C, Bennett JC, et al
    Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: the PSERENADE project.
    J Infect. 2025 Jan 24:106426. doi: 10.1016/j.jinf.2025.106426.
    >> Share

  25. SILVA SOUZA M, Pires Farias J, de Souza Ferreira LC, Amorim JH, et al
    Declining COVID-19 vaccination coverage in Brazil: A global health warning.
    J Infect. 2025;90:106418.
    >> Share

  26. ZHANG S, Liu J
    Optimization of Diphtheria, Tetanus and Pertussis (DTP) vaccination strategy in China.
    J Infect. 2025;90:106416.
    >> Share

  27. FENG S, Bibi S, Aley PK, Cappuccini F, et al
    Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
    J Infect. 2025;90:106423.
    >> Share

  28. RJOOB K, Antonelli M, Murray B, Molteni E, et al
    Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post COVID-19 Syndrome After SARS-CoV-2 Vaccination Versus Influenza Vaccination.
    J Infect. 2025 Jan 10:106406. doi: 10.1016/j.jinf.2024.106406.
    >> Share

  29. GEHRT L, Moller S, Englund H, Laake I, et al
    Vaccination against measles-mumps-rubella and rates of non-targeted infectious disease hospitalisations: Nationwide register-based cohort studies in Denmark, Finland, Norway, and Sweden.
    J Infect. 2025 Jan 7:106365. doi: 10.1016/j.jinf.2024.106365.
    >> Share

  30. ONG DS, Harris M, Hart JD, Russell FM, et al
    Lack of correlation between school reopening and trends in adult COVID-19 hospitalisations and death rates during the Delta and early Omicron periods: an ecological analysis of five countries.
    J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390.
    >> Share

  31. JORDA A, Prager M, Pracher L, Haselwanter P, et al
    Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised, Double-blind, Placebo-contro
    J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405.
    >> Share

    December 2024
  32. YANG Y, Shen X, Hu H, Wang Y, et al
    The need for inclusion of the Hib vaccine in mainland national immunization program in China.
    J Infect. 2024 Dec 23:106386. doi: 10.1016/j.jinf.2024.106386.
    >> Share

  33. MOK CKP, Tang YS, Tan CW, Chong KC, et al
    Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
    J Infect. 2024;90:106374.
    >> Share

  34. BORROW R, Campbell H, Caugant DA, Cherkaoui A, et al
    Global Meningococcal Initiative: Insights on antibiotic resistance, control strategies and advocacy efforts in Western Europe.
    J Infect. 2024;89:106335.
    >> Share

    November 2024
  35. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    >> Share

  36. CHOW KN, Tsang YW, Chan YH, Telaga SA, et al
    The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis.
    J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358.
    >> Share

  37. MCLEOD C, Dymock M, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
    J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346.
    >> Share

  38. MAHTAB S, Madewell ZJ, Baillie V, Dangor Z, et al
    Etiologies and Comorbidities of Meningitis Deaths in Children Under 5 Years in High-Mortality Settings: Insights from the CHAMPS Network in the Post-Pneumococcal Vaccine Era.
    J Infect. 2024 Nov 7:106341. doi: 10.1016/j.jinf.2024.106341.
    >> Share

  39. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    >> Share

  40. LIU Y, Yu D, Wang K, Ye Q, et al
    Global resurgence of pertussis: A perspective from China.
    J Infect. 2024;89:106289.
    >> Share

    October 2024
  41. WANG H, Zhou Y, Chu L, Chen K, et al
    Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
    J Infect. 2024;89:106333.
    >> Share

  42. CHEN X, Meng X, Wu Q, Lim WW, et al
    Assessment of Neutralizing Antibody Response as a Correlate of Protection against Symptomatic SARS-CoV-2 Infections after Administration of two doses of the CoronaVac inactivated COVID-19 Vaccine: A Phase III Randomized Controlled Trial.
    J Infect. 2024 Oct 16:106315. doi: 10.1016/j.jinf.2024.106315.
    >> Share

  43. MADSEN AMR, Gehrt L, Schaltz-Buchholzer F, Moller S, et al
    Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: a randomised clinical trial.
    J Infect. 2024 Oct 16:106319. doi: 10.1016/j.jinf.2024.106319.
    >> Share

  44. MARCHESE AM, Fries L, Beyhaghi H, Vadivale M, et al
    Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines.
    J Infect. 2024 Oct 15:106317. doi: 10.1016/j.jinf.2024.106317.
    >> Share

  45. MATUSALI G, Cimini E, Mazzotta V, Colavita F, et al
    Mpox Immune response elicited by MVA-BN vaccine over 12 months of follow-up.
    J Infect. 2024;89:106309.
    >> Share

  46. HANI E, Abdullahi F, Bertran M, Eletu S, et al
    Trends in invasive Haemophilus influenzae serotype b (Hib) disease in England: 2012/13 to 2022/23.
    J Infect. 2024;89:106247.
    >> Share

    September 2024
  47. NANQUE LM, Varma A, Thysen SM, Benn CS, et al
    Effect of a campaign with oral polio vaccine on general health: A cluster-randomised trial in rural Guinea-Bissau.
    J Infect. 2024 Sep 30:106302. doi: 10.1016/j.jinf.2024.106302.
    >> Share

  48. BENNETT C, Hoosain Z, Koen A, Lalloo U, et al
    Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial.
    J Infect. 2024 Sep 27:106285. doi: 10.1016/j.jinf.2024.106285.
    >> Share

  49. KIRWAN PD, Foulkes S, Munro K, Sparkes D, et al
    Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024.
    J Infect. 2024 Sep 27:106293. doi: 10.1016/j.jinf.2024.106293.
    >> Share

  50. RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al
    N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.
    J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288.
    >> Share

  51. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    >> Share

  52. FAUSTINI SE, Hodson J, Birtwistle J, Whitelegg A, et al
    Comparison of short- and long-term humoral immune responses to pneumococcal polysaccharide and glycoconjugate vaccines in an HIV-infected population.
    J Infect. 2024 Sep 24:106282. doi: 10.1016/j.jinf.2024.106282.
    >> Share

  53. CHRISTENSEN J, Johansen ND, Janstrup KH, Modin D, et al
    Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the DANFLU-1 randomized clinical trial.
    J Infect. 2024 Sep 18:106276. doi: 10.1016/j.jinf.2024.106276.
    >> Share

  54. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    Corrigendum to "The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials" [J Infect 89 (2024) 106187].
    J Infect. 2024;89:106270.
    >> Share

    August 2024
  55. AZIZ AB, Sugimoto JD, Hong SL, You YA, et al
    Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: a cluster randomised analysis.
    J Infect. 2024 Aug 30:106260. doi: 10.1016/j.jinf.2024.106260.
    >> Share

  56. GRAM MA, Thiesson EM, Pihlstrom N, Perala J, et al
    Comparative effectiveness of bivalent BA.4-5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study.
    J Infect. 2024;89:106261.
    >> Share

  57. FOULKES S, Evans J, Neill C, Bishop J, et al
    Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among healthcare workers: a cross-sectional survey in the SIREN cohort.
    J Infect. 2024 Aug 28:106259. doi: 10.1016/j.jinf.2024.106259.
    >> Share

  58. FRYER HA, Geers D, Gommers L, Zaeck LM, et al
    Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    J Infect. 2024 Aug 8:106246. doi: 10.1016/j.jinf.2024.106246.
    >> Share

  59. MESSINA NL, Pittet LF, McDonald E, Moore C, et al
    BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial.
    J Infect. 2024 Aug 8:106245. doi: 10.1016/j.jinf.2024.106245.
    >> Share

  60. FAN C, Yang Y, Zhan S, Sun X, et al
    The effectiveness and impact of the enterovirus 71 vaccine on the onset of hand, foot, and mouth disease in children aged
    J Infect. 2024;89:106244.
    >> Share

  61. ALABI A, Kokou K, Mahmoudou S, Kavishna R, et al
    Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-DeltaG-ZEBOV-GP in a sub-Saharan African paediatric population: a randomised controlled, open-label trial in children aged 1-12 years living in Lambarene, Gabon.
    J Infect. 2024 Aug 7:106237. doi: 10.1016/j.jinf.2024.106237.
    >> Share

  62. QUEK AML, Wang S, Teng O, Shunmuganathan B, et al
    Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals.
    J Infect. 2024 Aug 7:106238. doi: 10.1016/j.jinf.2024.106238.
    >> Share

  63. SILVA-COSTA C, Gomes-Silva J, Pinho M, Friaes A, et al
    Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19 pandemic was not associated with significant serotype changes.
    J Infect. 2024 Aug 6:106242. doi: 10.1016/j.jinf.2024.106242.
    >> Share

    July 2024
  64. ANDREWS N, Osuntoki I, Stowe J, Kirsebom FCM, et al
    The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in England 2022/23.
    J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221.
    >> Share

  65. GRISKAITIS M, Thielemann I, Schonfeld V, Falman A, et al
    Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.
    J Infect. 2024;89:106228.
    >> Share

  66. WANG B, Mohammed H, Andraweera P, McMillan M, et al
    Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.
    J Infect. 2024 Jul 8:106225. doi: 10.1016/j.jinf.2024.106225.
    >> Share

    June 2024
  67. DU Z, Wang S, Chen R, Shan S, et al
    Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults.
    J Infect. 2024;89:106211.
    >> Share

  68. GONG X, Peng L, Wang F, Liu J, et al
    Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    J Infect. 2024;89:106208.
    >> Share

  69. PEREZ-GARCIA C, Sempere J, de Miguel S, Hita S, et al
    Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023).
    J Infect. 2024;89:106204.
    >> Share

  70. ZHAI K, Dong J, Zeng J, Cheng P, et al
    Global Antigenic Landscape and Vaccine Recommendation Strategy for Low Pathogenic Avian Influenza A(H9N2) Viruses.
    J Infect. 2024 Jun 18:106199. doi: 10.1016/j.jinf.2024.106199.
    >> Share

  71. AUDRAN R, Karoui O, Donnet L, Soumas V, et al
    Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
    J Infect. 2024 Jun 17:106205. doi: 10.1016/j.jinf.2024.106205.
    >> Share

  72. MIKOLAJCZYK R, Diexer S, Klee B, Pfrommer L, et al
    Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
    J Infect. 2024 Jun 17:106206. doi: 10.1016/j.jinf.2024.106206.
    >> Share

  73. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron.
    J Infect. 2024;88:106165.
    >> Share

  74. TSANG RSW, Deceuninck G, Meilleur C, Zhou J, et al
    Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex.
    J Infect. 2024;88:106163.
    >> Share

    May 2024
  75. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
    J Infect. 2024;89:106187.
    >> Share

  76. AMANO M, Ichikawa Y, Matsumoto S, Higashi-Kuwata N, et al
    Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination.
    J Infect. 2024;89:106179.
    >> Share

  77. PANG CWK, Vale R, Lao KS, Khan AT, et al
    Increased Incidence of Invasive Pneumococcal Disease in Hong Kong in 2023.
    J Infect. 2024 May 11:106178. doi: 10.1016/j.jinf.2024.106178.
    >> Share

  78. KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al
    Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177.
    >> Share

    April 2024
  79. MENGYANG G, Yahong H, Qinghong M, Wei S, et al
    Resurgence and atypical patterns of pertussis in China.
    J Infect. 2024;88:106140.
    >> Share

    March 2024
  80. NG M, S D, L W, R B, et al
    Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology.
    J Infect. 2024 Mar 27:106145. doi: 10.1016/j.jinf.2024.106145.
    >> Share

  81. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
    >> Share

  82. SUN L, Man Q, Zhang H, Xia S, et al
    Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination.
    J Infect. 2024;88:106138.
    >> Share

  83. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    >> Share

  84. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    >> Share

    February 2024
  85. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
    AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
    J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
    >> Share

    September 2023
  86. CLARK SA, Campbell H, Ribeiro S, Bertran M, et al
    Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England.
    J Infect. 2023 Sep 7:S0163-4453(23)00504-2. doi: 10.1016/j.jinf.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016